This cross-sectional study evaluates serum HE4 and CA-125 levels during neoadjuvant chemotherapy in advanced ovarian cancer, indicating predictive insights into treatment response.
Key Points
The study shows that HE4 levels significantly decrease with effective chemotherapy response in advanced ovarian cancer patients.
Patients with no response to chemotherapy had a mean HE4 level of 539.03, while responders had a mean of 140.58, indicating a strong correlation.
Cross-sectional comparative analysis was performed on serum biomarker levels among patients receiving neoadjuvant chemotherapy from January to December 2022.
Findings suggest effective monitoring of chemotherapy response, but further research is necessary to explore the long-term impact of HE4 and CA-125 on survival rates.